UBS Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $364M | Buy |
396,100
+63,316
| +19% | +$64.2M | 0.05% | 358 |
|
|
2025
Q4 | $358M | Sell |
332,784
-61,610
| -16% | -$58.9M | 0.06% | 333 |
|
|
2025
Q3 | $301M | Sell |
394,394
-5,336
| -1% | -$3.97M | 0.05% | 392 |
|
|
2025
Q2 | $312M | Sell |
399,730
-54,970
| -12% | -$42.7M | 0.05% | 355 |
|
|
2025
Q1 | $376M | Buy |
454,700
+208,400
| +85% | +$173M | 0.07% | 283 |
|
|
2024
Q4 | $190M | Sell |
246,300
-33,000
| -12% | -$27.3M | 0.04% | 544 |
|
|
2024
Q3 | $247M | Buy |
279,300
+94,800
| +51% | +$85.2M | 0.05% | 325 |
|
|
2024
Q2 | $167M | Sell |
184,500
-26,700
| -13% | -$21.4M | 0.04% | 416 |
|
|
2024
Q1 | $164M | Sell |
211,200
-54,182
| -20% | -$38.6M | 0.04% | 424 |
|
|
2023
Q4 | $155M | Buy |
265,382
+157,113
| +145% | +$91.7M | 0.05% | 398 |
|
|
2023
Q3 | $58.2M | Buy |
108,269
+51,569
| +91% | +$26.6M | 0.02% | 752 |
|
|
2023
Q2 | $26.6M | Buy |
56,700
+4,500
| +9% | +$1.89M | 0.01% | 1224 |
|
|
2023
Q1 | $17.9M | Sell |
52,200
-16,107
| -24% | -$5.43M | 0.01% | 1484 |
|
|
2022
Q4 | $25M | Buy |
68,307
+37,307
| +120% | +$13.2M | 0.01% | 1258 |
|
|
2022
Q3 | $10M | Buy |
31,000
+5,000
| +19% | +$1.58M | ﹤0.01% | 1793 |
|
|
2022
Q2 | $8.43M | Sell |
26,000
-8,400
| -24% | -$2.52M | ﹤0.01% | 1940 |
|
|
2022
Q1 | $9.85M | Sell |
34,400
-127,496
| -79% | -$32.8M | ﹤0.01% | 1949 |
|
|
2021
Q4 | $44.7M | Sell |
161,896
-47,568
| -23% | -$12.1M | 0.01% | 1022 |
|
|
2021
Q3 | $48.4M | Buy |
209,464
+18,400
| +10% | +$4.54M | 0.02% | 885 |
|
|
2021
Q2 | $43.9M | Sell |
191,064
-25,000
| -12% | -$5.02M | 0.01% | 935 |
|
|
2021
Q1 | $40.4M | Buy |
216,064
+7,764
| +4% | +$1.52M | 0.01% | 976 |
|
|
2020
Q4 | $35.2M | Buy |
208,300
+143,300
| +220% | +$21.4M | 0.01% | 982 |
|
|
2020
Q3 | $9.62M | Buy |
65,000
+40,000
| +160% | +$6.19M | ﹤0.01% | 1665 |
|
|
2020
Q2 | $4.11M | Buy |
+25,000
| New | +$3.84M | ﹤0.01% | 2202 |
|
|
2020
Q1 | – | Sell |
-99,100
| Closed | -$13M | – | 8197 |
|
|
2019
Q4 | $13M | Buy |
99,100
+500
| +0.5% | +$58K | ﹤0.01% | 1714 |
|
|
2019
Q3 | $11M | Sell |
98,600
-61,300
| -38% | -$6.82M | ﹤0.01% | 1692 |
|
|
2019
Q2 | $17.7M | Sell |
159,900
-79,100
| -33% | -$9.31M | 0.01% | 1296 |
|
|
2019
Q1 | $31M | Sell |
239,000
-63,500
| -21% | -$7.72M | 0.01% | 883 |
|
|
2018
Q4 | $35M | Sell |
302,500
-104,900
| -26% | -$11.7M | 0.02% | 774 |
|
|
2018
Q3 | $43.7M | Buy |
407,400
+150,000
| +58% | +$15M | 0.02% | 747 |
|
|
2018
Q2 | $22M | Sell |
257,400
-500
| -0.2% | -$41.1K | 0.01% | 1105 |
|
|
2018
Q1 | $20M | Buy |
257,900
+257,400
| +51,480% | +$20.7M | 0.01% | 1162 |
|
|
2017
Q4 | $42K | Sell |
500
-2,800
| -85% | -$238K | ﹤0.01% | 5978 |
|
|
2017
Q3 | $282K | Buy |
+3,300
| New | +$271K | ﹤0.01% | 4620 |
|
|
2017
Q2 | – | Sell |
-83,300
| Closed | -$7.01M | – | 7841 |
|
|
2017
Q1 | $7.01M | Sell |
83,300
-667,000
| -89% | -$53.4M | ﹤0.01% | 1792 |
|
|
2016
Q4 | $55.2M | Buy |
750,300
+665,100
| +781% | +$49.5M | 0.03% | 498 |
|
|
2016
Q3 | $6.84M | Buy |
85,200
+70,500
| +480% | +$5.64M | ﹤0.01% | 1727 |
|
|
2016
Q2 | $1.16M | Buy |
14,700
+1,300
| +10% | +$97.9K | ﹤0.01% | 3251 |
|
|
2016
Q1 | $965K | Sell |
13,400
-146,441
| -92% | -$11.1M | ﹤0.01% | 3285 |
|
|
2015
Q4 | $13.5M | Buy |
159,841
+99,741
| +166% | +$8.28M | 0.01% | 1202 |
|
|
2015
Q3 | $5.03M | Sell |
60,100
-25,000
| -29% | -$2.11M | ﹤0.01% | 1915 |
|
|
2015
Q2 | $7.11M | Hold |
85,100
| – | – | ﹤0.01% | 1757 |
|
|
2015
Q1 | $6.18M | Buy |
85,100
+53,400
| +168% | +$3.8M | ﹤0.01% | 1881 |
|
|
2014
Q4 | $2.19M | Buy |
+31,700
| New | +$2.14M | ﹤0.01% | 2823 |
|
Other funds holding LLY
VCM
VPM
UBS Group's LLY Position: Q1 2026 in Review
UBS Group increased its Eli Lilly (LLY) stake by 13% in Q1 2026, buying an estimated $486M and bringing the position to 4,043,568 shares worth $3.72B. The position accounts for 0.56% of the portfolio, ranked #16.
UBS Group first reported a position in LLY in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.83B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- UBS Group held 4,043,568 shares of Eli Lilly worth $3.72B as of Q1 2026.
- UBS Group bought 479,648 Eli Lilly shares in Q1 2026, an estimated $486M.
- Eli Lilly made up 0.56% of UBS Group's portfolio in Q1 2026, its #16 holding.
- UBS Group first reported a position in Eli Lilly in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Eli Lilly position peaked at $3.83B in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.